Welcome to SynAging SAS

your R&D partner for in vitro and in vivo induced phenotypic models, accelerating drug discovery for proteopathic diseases.

News

SynAging is represented at the following conferences:

AD/PD 2015 Meeting,
2015, March 18-22, Nice, France

52.EMBO | EMBL Symposium: Mechanisms of Neurodegeneration
2015, June 14-17 , Heidelberg, Germany

Society for Neuroscience Meeting
2015, October 17-21, Chicago, USA

BioEurope
2015, November 2-4, Munich, Germany

 

Press & Publications

Most recent SynAging’s article published with University Medicine Goettingen.
Download PDF, 1.1 MB

 

SynAging Provides Innovative Models for Neurodegenerative Diseases

Neurological diseases are among the most common threats to human health and difficult to treat. Millions of people are affected, especially in aging societies. Today there are no cures for neurological diseases and effective drug therapies are very much needed. For decades drug development programs addressing common diseases of the central nervous system (CNS) show particularly high failure rates and little progress. Clearly, clinicians and researchers require much better in vitro and in vivo models to identify and develop new, effective and safe drugs.

In recent years, neurobiology has helped to improve the understanding of brain physiology and neurochemical and biochemical function and in healthy and diseased states. SynAging builds on the latest findings and provides drug developers with practical and reliable models that best emulate CNS diseases under investigation.

SynAging focuses on toxic oligomeric protein assemblies, which are involved in the earliest stages of age-related neurodegenerative diseases.

See Science and Technology.

 

SynAging is a contract research organization (CRO) which provides:

  • Disease relevance to facilitate translation into clinical development
  • High reproducibility and reliability
  • Results in a timely manner
  • Cost-effective services

SynAging’s services involve proprietary models e.g. for Alzheimer’s Dementia (AD) and are continuously expanded to cover other neurological indications by providing new and better models.